A Phase 1 interventional study of Lisdexamfetamine Dimesylate (LDX) and Immediate Release Mixed Amphetamine Salts (MAS-IR) in Attention-Deficit Hyperactivity Disorder, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 46th largest by enrollment, is one of 5 that started in 2010, is one of 2 in phase 1, and was the 23rd registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 5 started in 2010.
This study's enrollment of 18 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 50th largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2010, is one of 5 in phase 1, and was the 31st registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the sensitivity and responsiveness of a standardized, validated, computer-based, battery of neuro-psychometric tests in adults with ADHD.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
Drug: Lisdexamfetamine Dimesylate (LDX)
Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
Drug: Immediate Release Mixed Amphetamine Salts (MAS-IR)
Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
Drug: LDX Placebo + MAS-IR Placebo
Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
Power of Attention Score
The Power of Attention score reflects the ability to focus attention, and is calculated as the sum of the reaction time, measured in milliseconds, from 3 attention tests (Simple Reaction Time, Choice Reaction Time, and Digit Vigilance Speed). Faster performance (lower times) reflects more intense concentration. A decrease in the Power of Attention score indicates improvement.
Time frame: pre-dose and at 1, 2, 3, 4, 5, 8, 12, 14 and 16 hours post-dose on Day 7
Conners Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S) Subscale Total Score (T-Score): Inattention/Memory Problems
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
Time frame: 2 and 14 hours post-dose on Day 7
CAARS-S:S Subscale T-Score: Hyperactivity/Restlessness
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
Time frame: 2 and 14 hours post-dose on Day 7
CAARS-S:S Subscale T-Score: Impulsivity/Emotional Liability
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
Time frame: 2 and 14 hours post-dose on Day 7
CAARS-S:S Subscale T-Score: Problems With Self-Concept
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
Time frame: 2 and 14 hours post-dose on Day 7
CAARS-S:S Subscale T-Score: Attention Deficit Hyperactivity Disorder (ADHD) Index
Consists of 12 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
Time frame: 2 and 14 hours post-dose on Day 7
| Milestone | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | Placebo First, Then LDX 50 mg, Then MAS-IR 20 mg | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 3 | 2 | 3 |
| Completed | 3 | 4 | 3 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | Placebo First, Then LDX 50 mg, Then MAS-IR 20 mg | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 3 | 2 | 3 |
| Completed | 3 | 3 | 3 | 3 | 2 | 3 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | Placebo First, Then LDX 50 mg, Then MAS-IR 20 mg | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 2 | 3 |
| Completed | 3 | 3 | 3 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The Power of Attention score reflects the ability to focus attention, and is calculated as the sum of the reaction time, measured in milliseconds, from 3 attention tests (Simple Reaction Time, Choice Reaction Time, and Digit Vigilance Speed). Faster performance (lower times) reflects more intense concentration. A decrease in the Power of Attention score indicates improvement.
| milliseconds | LDX 50 mg | MAS-IR 20 mg | Placebo |
|---|---|---|---|
| half an hour prior to dosing | 1260.7 ± 34.000 | 1324.1 ± 47.142 | 1272.8 ± 33.729 |
| 1 hour post-dose | 1244.6 ± 32.887 | 1307.4 ± 42.908 | 1253.1 ± 24.174 |
| 2 hours post-dose | 1315.5 ± 67.246 | 1255.0 ± 33.905 | 1296.2 ± 39.808 |
| 3 hours post-dose | 1219.1 ± 33.428 | 1229.6 ± 37.865 | 1301.0 ± 40.864 |
| 4 hours post-dose | 1225.9 ± 40.192 | 1236.5 ± 36.839 | 1275.4 ± 35.302 |
| 5 hours post-dose | 1179.6 ± 35.022 | 1251.4 ± 42.607 | 1330.3 ± 49.623 |
| 8 hours post-dose | 1212.0 ± 36.113 | 1259.3 ± 35.883 | 1304.5 ± 43.802 |
| 12 hours post-dose | 1232.4 ± 48.183 | 1239.3 ± 38.465 | 1262.1 ± 40.795 |
| 14 hours post-dose | 1199.3 ± 35.947 | 1270.1 ± 39.539 | 1270.5 ± 44.814 |
| 16 hours post-dose | 1202.6 ± 37.135 | 1255.9 ± 36.378 | 1270.3 ± 48.581 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
| Units on a scale | LDX 50 mg | MAS-IR 20 mg | Placebo |
|---|---|---|---|
| 2 hours post-dose | 66.16 ± 2.927 | 63.39 ± 3.319 | 64.92 ± 2.775 |
| 14 hours post-dose | 65.78 ± 3.029 | 64.45 ± 2.483 | 66.33 ± 2.398 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
| Units on a scale | LDX 50 mg | MAS-IR 20 mg | Placebo |
|---|---|---|---|
| 2 hours post-dose | 64.21 ± 2.996 | 63.62 ± 3.372 | 63.28 ± 3.063 |
| 14 hours post-dose | 65.08 ± 2.837 | 63.41 ± 2.763 | 65.74 ± 2.597 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
| Units on a scale | LDX 50 mg | MAS-IR 20 mg | Placebo |
|---|---|---|---|
| 2 hours post-dose | 55.46 ± 2.931 | 54.58 ± 3.470 | 54.66 ± 3.421 |
| 14 hours post-dose | 57.82 ± 3.479 | 51.53 ± 2.802 | 55.78 ± 2.773 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
| Units on a scale | LDX 50 mg | MAS-IR 20 mg | Placebo |
|---|---|---|---|
| 2 hours post-dose | 58.71 ± 3.533 | 59.78 ± 3.390 | 58.40 ± 3.279 |
| 14 hours post-dose | 59.68 ± 3.841 | 59.54 ± 3.574 | 59.68 ± 3.055 |
Consists of 12 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.
| Units on a scale | LDX 50 mg | MAS-IR 20 mg | Placebo |
|---|---|---|---|
| 2 hours post-dose | 64.82 ± 3.147 | 63.90 ± 3.766 | 64.59 ± 3.681 |
| 14 hours post-dose | 66.56 ± 3.714 | 63.09 ± 2.945 | 64.85 ± 3.118 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDX 50 mg | — | 0/18 (0%) | 12/18 (66.7%) |
| MAS-IR 20 mg | — | 0/17 (0%) | 9/17 (52.9%) |
| Placebo | — | 0/17 (0%) | 8/17 (47.1%) |
| Event | LDX 50 mg | MAS-IR 20 mg | Placebo |
|---|---|---|---|
| Dry MouthGastrointestinal disorders | 6/18 | 4/17 | 3/17 |
| Decreased AppetiteMetabolism and nutrition disorders | 3/18 | 4/17 | 1/17 |
| HeadacheNervous system disorders | 1/18 | 1/17 | 3/17 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/18 | 2/17 | 0/17 |
| Feeling JitteryGeneral disorders | 1/18 | 2/17 | 0/17 |
| Heart Rate IncreasedInvestigations | 2/18 | 0/17 | 0/17 |
| DizzinessNervous system disorders | 1/18 | 1/17 | 1/17 |
| SedationNervous system disorders | 0/18 | 1/17 | 0/17 |
| InsomniaPsychiatric disorders | 1/18 | 1/17 | 0/17 |
| NervousnessPsychiatric disorders | 0/18 | 1/17 | 0/17 |
| Age, Continuous(years) | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | Placebo First, Them LDX 50 mg, Then MAS-IR 20 mg | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 25.0 ± 1.00 | 24.8 ± 6.70 | 30.3 ± 6.11 | 31.3 ± 11.37 | 53.0 ± 0.00 | 30.0 ± 11.36 | 30.8 ± 10.75 |
| Age, Customized(Participants) | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | Placebo First, Them LDX 50 mg, Then MAS-IR 20 mg | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg | Total |
|---|---|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 55 years | 3 | 4 | 3 | 3 | 2 | 3 | 18 |
| >=56 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | Placebo First, Them LDX 50 mg, Then MAS-IR 20 mg | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 1 | 1 | 2 | 7 |
| Male | 3 | 2 | 2 | 2 | 1 | 1 | 11 |
| Region of Enrollment(Participants) | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | Placebo First, Them LDX 50 mg, Then MAS-IR 20 mg | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg | Total |
|---|---|---|---|---|---|---|---|
| United States | 3 | 4 | 3 | 3 | 2 | 3 | 18 |
Ran from Jan 2010 to primary completion in Mar 2010, 2 months.
Results were first posted in Feb 2011, 10 months after primary completion.
Of 21 industry-sponsored phase 1 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 2 months of starting (the median); a quarter within 1 and three quarters within 7. This study's 2 months is close to that.
Counting every sponsor, half of 35 studies reached it within 9 months; a quarter within 2 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →